Global Oncology Academy

Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Global Oncology Academy
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Global Oncology Academy
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Evolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
Evolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
Global Oncology Academy
Evolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
- Daniel J. George, MD
ADT Monotherapy for mHSPC: How to Identify the Right Patients
ADT Monotherapy for mHSPC: How to Identify the Right Patients
Global Oncology Academy
ADT Monotherapy for mHSPC: How to Identify the Right Patients
- Daniel J. George, MD
Advancing Patient-Centered Care in HER2-Positive Metastatic Breast Cancer
Advancing Patient-Centered Care in HER2-Positive Metastatic Breast Cancer
Global Oncology Academy
Advancing Patient-Centered Care in HER2-Positive Metastatic Breast Cancer
- Megan Kruse, MD
Oral Contraceptives and Endometrial Cancer: Examining a Potential Dose-Response Protective Effect
Oral Contraceptives and Endometrial Cancer: Examining a Potential Dose-Response Protective Effect
Project Oncology®
Oral Contraceptives and Endometrial Cancer: Examining a Potential Dose-Response Protective Effect
Colorectal Cancer Screening: Evaluating the Cost-Effectiveness of Noninvasive Options
Colorectal Cancer Screening: Evaluating the Cost-Effectiveness of Noninvasive Options
Clinician's Roundtable
Colorectal Cancer Screening: Evaluating the Cost-Effectiveness of Noninvasive Options
- Brian P. McDonough, MD, FAAFP
- Carolyn Rutter, PhD
- Gloria Coronado, PhD
Cost Considerations for Colorectal Cancer Screening: Examining the Data
Cost Considerations for Colorectal Cancer Screening: Examining the Data
Clinician's Roundtable
Cost Considerations for Colorectal Cancer Screening: Examining the Data

Medical News

Medical News
Genomic Risk Assessment: Predicting the Progression of Multiple Myeloma
05/22/2025
Read more
Medical News
mHealth Apps and Cancer Screening: Community Engagement Approaches
05/22/2025
Read more
Medical News
Rapid Genetic Testing: Accelerating Brain Tumor Diagnosis
05/21/2025
Read more
Medical News
Home-Based Digital Counseling and Colorectal Cancer Screening
05/20/2025
Read more

See more news

CME/CE

Second-line Chemotherapy Options in Metastatic PDAC
Second-line Chemotherapy Options in Metastatic PDAC
MinuteCE®
Second-line Chemotherapy Options in Metastatic PDAC
0.25 program credits
- Efrat Dotan, MD
0.25 program credits
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit

Clinical Practice

Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
Global Oncology Academy
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Project Oncology®
Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Project Oncology®
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
- Charles Turck, PharmD, BCPS, BCCCP
- Daniel Wolff, MD
Oral Contraceptives and Endometrial Cancer: Examining a Potential Dose-Response Protective Effect
Oral Contraceptives and Endometrial Cancer: Examining a Potential Dose-Response Protective Effect
Project Oncology®
Oral Contraceptives and Endometrial Cancer: Examining a Potential Dose-Response Protective Effect

Programs

Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Global Oncology Academy
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
- Gerard A. Silvestri MD, MS, Master FCCP
- Anurag Singh, MD
- Adam H. Fox, MD, MSc
- Mariam Alexander, MD, PhD
Prostate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
Prostate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
Clinician's Roundtable
Prostate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
- Ihtisham Ahmad
Strategic Sequencing in Steroid-Refractory Chronic GVHD: Adapting to a New Landscape
Strategic Sequencing in Steroid-Refractory Chronic GVHD: Adapting to a New Landscape
Project Oncology®
Strategic Sequencing in Steroid-Refractory Chronic GVHD: Adapting to a New Landscape
- Jennifer Caudle, DO
- Doris M. Ponce, MD, MS
Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
Global Oncology Academy
Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
- Paolo Tarantino, MD